Adaptive Biotechnologies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADPT and other ETFs, options, and stocks.

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. 

CEO
Chad Robins
CEOChad Robins
Employees
624
Employees624
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
2009
Founded2009
Employees
624
Employees624

ADPT Key Statistics

Market cap
3.58B
Market cap3.58B
Price-Earnings ratio
-68.33
Price-Earnings ratio-68.33
Dividend yield
Dividend yield
Average volume
4.81M
Average volume4.81M
High today
$23.00
High today$23.00
Low today
$20.90
Low today$20.90
Open price
$21.45
Open price$21.45
Volume
3.28M
Volume3.28M
52 Week high
$23.00
52 Week high$23.00
52 Week low
$9.96
52 Week low$9.96

Stock Snapshot

As of today, Adaptive Biotechnologies(ADPT) shares are valued at $23.00. The company's market cap stands at 3.58B, with a P/E ratio of -68.33.

On 2026-07-01, Adaptive Biotechnologies(ADPT) stock moved within a range of $20.90 to $23.00. With shares now at $23.00, the stock is trading +10.0% above its intraday low and 0.0% below the session's peak.

Trading volume for Adaptive Biotechnologies(ADPT) stock has reached 3.28M, versus its average volume of 4.81M.

The stock's 52-week range extends from a low of $9.96 to a high of $23.00.

The stock's 52-week range extends from a low of $9.96 to a high of $23.00.

ADPT News

Investing.com 2d
Adaptive Biotechnologies chief commercial officer sells $102,500 in stock - Investing.com

...

Adaptive Biotechnologies chief commercial officer sells $102,500 in stock - Investing.com
Simply Wall St 3d
Adaptive Biotechnologies Plans A Business Split, Is The Valuation Already Full?

Adaptive Biotechnologies (ADPT) is back in focus after announcing plans to separate its Minimal Residual Disease and Immune Medicine businesses, alongside compl...

Adaptive Biotechnologies Plans A Business Split, Is The Valuation Already Full?
TipRanks 3d
Adaptive Biotechnologies price target raised to $22 from $21 at Guggenheim

Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $22 from $21 and keeps a Buy rating on the shares. The firm adjusted models and...

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More ADPT News

Simply Wall St 5d
Does Adaptive Biotechnologies’ Convertible Raise and Split Plan Reveal a New Strategic Center of Gravity?

Earlier in June 2026, Adaptive Biotechnologies completed a US$300,000,000 zero-coupon, senior unsecured convertible notes offering due July 1, 2031, shortly aft...

Does Adaptive Biotechnologies’ Convertible Raise and Split Plan Reveal a New Strategic Center of Gravity?

People also own

Based on the portfolios of people who own ADPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.